NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates

分组1 - NeuroPace, Inc. reported a quarterly loss of $0.08 per share, better than the Zacks Consensus Estimate of a loss of $0.14, and improved from a loss of $0.18 per share a year ago, resulting in an earnings surprise of +41.48% [1] - The company achieved revenues of $26.59 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 2.47%, and showing an increase from $21.47 million in the same quarter last year [2] - NeuroPace has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has underperformed the market, losing about 8.4% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.23 on revenues of $21.7 million, and for the current fiscal year, it is -$0.71 on revenues of $98.65 million [7] - The Medical - Instruments industry, to which NeuroPace belongs, is currently in the top 33% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]